Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug shows promise in early cancer trial

NCT ID NCT02937272

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 adults whose cancer has not responded to standard therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LY3200882 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for certain solid tumors.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet proven to work. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Camurati-Engelmann Syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

  • CHRU de Lille

    Lille, 59037, France

  • Calvary Mater Newcastle

    Newcastle, New South Wales, 2298, Australia

  • Charité Campus Virchow-Klinikum

    Berlin, 12203, Germany

  • Greenslopes Private Hospital

    Greenslopes, Queensland, 4120, Australia

  • Gustave Roussy

    Villejuif, 94805, France

  • Hopital Saint-Louis

    Paris, Cedex 10, 75475, France

  • Hospital Clínico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Istituto Clinico Humanitas

    Rozzano, Milano, 20089, Italy

  • National Cancer Center Hospital

    Chuo-Ku, Tokyo, 104-0045, Japan

  • Ospedale Policlinico Giambattista Rossi, Borgo Roma

    Verona, 37134, Italy

  • Princess Margaret Hospital (Ontario)

    Lai Chi Kok, Kowloon, Canada

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, 2010, Australia

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Universitätsklinikum Würzburg A. ö. R.

    Würzburg, Bavaria, 97080, Germany

  • Weill Cornell Medical College

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.